| Study |
N Total (# MZL) |
Year |
Treatment |
Response Rate |
PFS and OS |
| Sinha et al. [42] |
19 (3 MZL) |
2012 |
Bor+R+CHOP (frontline) |
ORR: 100% and CR: 68 |
[Seems the N should be reported in the same column for each studyà](N=19) 3yr PFS:89.5% and OS: 94.7% |
| Gerecitano et al. [43] |
57 (16 MZL) |
2011 |
R-CBorP (salvage) |
(N=57) Weekly ORR: 46% CR: 23%; Biweekly: ORR 64% CR: 36% |
NR |
| Friedberg et al. [44] |
31 (3 MZL) |
2011 |
Bor/Bendamustine/R (salvage) |
(N=31) ORR: 83%, |
(N=31) 2yr PFS: 47% |
| O’Connor et al. [21] |
77 (8 MZL) |
2010 |
Bor single agent (salvage) |
(N=77) ORR: 45%, CR: 10/77 13% |
NR |
| Di Bella et al.[26] |
60 (6 MZL) |
2010 |
Bor single agent (salvage) |
CR 1/6 (16.7%) SD 2/6 (33%) PD 3/6 (50%) |
(N=60) median PFS 5.1mons (r: 0.2-22.7); 2 yr. OS: 58% |
| De Vos et al.[45] |
18 (11 MZL) |
2009 |
Bor(1.3mg BIW) + R vs. Bor (1.6mg QW)+R |
Bor (1.3mg) MZL ORR 4/8 50% CR: |
Median PFS 10.0 mons |
| Witzig et al.[46] |
43 (3 MZL) |
2009 |
Lenalidomide single agent (salvage) |
MZL ORR: 0% SD: 2/3 66% PD: 1/3 33% |
NR |
| Kiesewetter et al. [19] |
18 (18 MALT) |
2013 |
Lenalidomide single agent |
ORR 61% (33% CR, 28% PR) |
Median FU: 20.3mons |
| Advani et al.[37] |
56 (1 MZL) |
2013 |
Ibrutinib single agent |
ORR 47% (0/1 MZL) |
Median PFS: 13.6monts |
| Kahl et al. [35] |
100 (16 MZL) |
2010 |
Bendamustine+R (Salvage) |
7 MALT lymphoma ORR 86% CR43% SD14%
9 NMZL: ORR 78% CR11% SD 22% |
(N=100) median FU: 11.8mons; PFS 9.3 mon |
| Friedberg et al.[47] |
76 (2 MZL) |
2008 |
Bendamustine single agent (salvage) |
2 MZL CR 1/2 50%; PR 1/2 50% |
(N=76) Median FU: 26mons; Median PFS: 7.13 mons; OS: NR |
| Robinson et al.[48] |
66 (2 MZL) |
2008 |
Bendamustine +R (salvage) |
(N=66) ORR 92% CR 41% |
(N=66) Median FU: 20mons; Median PFS: 23 mons; OS: NR |
| Rummel et al.[49] |
63 (6 MZL) |
2005 |
Bendamustine single agent (salvage) |
6 MZL: ORR 5/6 83%; CR 4/6 67% |
(N=63) Median PFS: 24 mons |
| Morschhauser et al.[41] |
82 (6 MZL) |
2009 |
Veltuzumab single agent (salvage) |
6 MZL: ORR 5/6 83%; CR 2/6 33% |
The two CRs were ongoing at 14.6 and 26.2 mons. |
Bor: Bortezomib; ORR: Overall Response Rate; CR: Complete Response; PR: Partial Response; PD: Progressive Disease; SD: Stable Disease; PFS: Progression-Free
Survival; OS: Overall Survival; MALT: Mucosa-Associated Lymphatic Tissue; CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone; QW: Weekly. NR: Not
Reported; r: Range; FU: Follow-up; R: Rituximab